SecBot SecBot
25-NSE ·Filed May 14, 2026

APLS

Apellis Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001354457-26-000449
Notable filing: 25-NSE
Actionable Insight • Neutral

The delisting is a routine administrative step following the completed acquisition. No further trading action is possible in APLS common stock. Monitor CVR milestone payments tied to SYFOVRE sales targets for potential value realization.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+1
Entry
$41.03
T+0 close · May 14, 2026 · via day close
Latest settled
0.00%
T+1 · $41.03
Vs SPY
+1.23%
α at T+1
Next horizon
T+5
due 6mo ago
  1. T+0 · May 14 $41.03entry
  2. T+1 · 6mo ago 0.00%α +1.23% · $41.03
  3. T+5 · due 6mo ago Pending
  4. T+20 · due 5mo ago Pending
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May 14, 2026, following the completion of Biogen's acquisition. The delisting is a procedural step after the merger closed, with APLS stockholders receiving $41.00 per share plus CVRs.

Key Facts

  • Form 25-NSE filed by Nasdaq Stock Market LLC to delist Apellis common stock under Rule 12d2-2(a)(3).
  • Effectiveness date is May 14, 2026, the same day as the filing.
  • Delisting follows Biogen's completed acquisition of Apellis for $41.00 per share plus CVRs.
  • The security is removed from listing and registration due to the merger, not due to any operational failure.

Financial Impact

No new financial impact; delisting is a procedural step after the $5.3B acquisition closed at $41.00/share plus CVRs.

Risk Factors

  • CVR milestone payments may not be achieved if SYFOVRE sales targets are missed.
  • No further liquidity in APLS common stock post-delisting.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
30% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000449
Document: 0001354457-26-000449-index-headers.html0001354457-26-000449
Document: 0001354457-26-000449-index.html0001354457-26-000449
Document: 0001354457-26-000449.txt0001354457-26-000449

Track record

5 reports on APLS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 26, 202624w ago 15-12G Neutral 6/10 No price data
  2. May 14, 202626w ago 25-NSE Neutral 2/10 Viewing Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
  3. May 14, 202626w ago 8-K Bullish 8/10 Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
  4. May 4, 202628w ago 8-K Neutral 2/10 Entry $40.97 to $40.97 · 0.00% −0.80% vs SPY
  5. Mar 27, 202633w ago Institutional Cluster Mixed 6/10 Entry $16.97 to $17.09 ▲ +0.71% +1.06% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens Wed (9h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026